Cortisol dysregulation: the bidirectional link between stress, depression, and type 2 diabetes mellitus

Annals of the New York Academy of Sciences

Volumn 1391, Issue 1, 2017, Pages 20-34

  Joseph, Joshua J ^a   Golden, Sherita H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cortisol; depression; diabetes; hypothalamic pituitary adrenal axis; stress

Indexed keywords

HYDROCORTISONE;

AUTONOMIC NERVOUS SYSTEM; CHRONIC STRESS; CIRCADIAN RHYTHM; DEPRESSION; DISEASE ASSOCIATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; MENTAL STRESS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY;

DEPRESSIVE DISORDER; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INSULIN RESISTANCE; PITUITARY-ADRENAL SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 84991702090     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13217     Document Type: Review

References (100)

1. Carlson, E.D. & R.M. Chamberlain. 2005. Allostatic load and health disparities: a theoretical orientation. Res. Nurs. Health 28: 306–315.
2. McEwen, B.S. & J.C. Wingfield. 2003. The concept of allostasis in biology and biomedicine. Horm. Behav. 43: 2–15.
3. McEwen, B.S. 2002. Sex, stress and the hippocampus: allostasis, allostatic load and the aging process. Neurobiol. Aging 23: 921–939.
4. Chrousos, G.P. 2009. Stress and disorders of the stress system. Nat. Rev. Endocrinol. 5: 374–381.
5. Flier, J.S., L.H. Underhill & B.S. McEwen. 1998. Protective and damaging effects of stress mediators. N. Engl. J. Med. 338: 171–179.
6. Seeman, T.E., B.H. Singer, C.D. Ryff, et al. 2002. Social relationships, gender, and allostatic load across two age cohorts. Psychosom. Med. 64: 395–406.
7. Mair, C.A., M.P. Cutchin & P.M. Kristen. 2011. Allostatic load in an environmental riskscape: the role of stressors and gender. Health Place 17: 978–987.
8. Golden, S.H., G.S. Wand, S. Malhotra, et al. 2011. Reliability of hypothalamic–pituitary–adrenal axis assessment methods for use in population-based studies. Eur. J. Epidemiol. 26: 511–525.
9. Champaneri, S., G.S. Wand, S.S. Malhotra, et al. 2010. Biological basis of depression in adults with diabetes. Curr. Diab. Rep. 10: 396–405.
10. Shomaker, L.B. et al. 2011. Longitudinal study of depressive symptoms and progression of insulin resistance in youth at risk for adult obesity. Diabetes Care 34: 2458–2463.
11. Hasan, S.S., A.M. Clavarino, A.A. Mamun & T. Kairuz. 2014. Incidence and risk of diabetes mellitus associated with depressive symptoms in adults: evidence from longitudinal studies. Diabetes Metab. Syndr. 8: 82–87.
12. Eaton, W.W., H. Armenian, J. Gallo, et al. 1996. Depression and risk for onset of type II diabetes: a prospective population-based study. Diabetes Care 19: 1097–1102.
13. Mezuk, B., W.W. Eaton, S. Albrecht & S.H. Golden. 2008. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 31: 2383–2390.
14. Carnethon, M.R., L.S. Kinder, J.M. Fair, et al. 2003. Symptoms of depression as a risk factor for incident diabetes: findings from the National Health and Nutrition Examination Epidemiologic Follow-up Study, 1971–1992. Am. J. Epidemiol. 158: 416–423.
15. Golden, S.H. et al. 2008. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 299: 2751–2759.
16. Anderson, R.J., K.E. Freedland, R.E. Clouse & P.J. Lustman. 2001. The prevalence of comorbid depression in adults with diabetes. Diabetes Care 24: 1069.
17. Katon, W. et al. 2004. Behavioral and clinical factors associated with depression among individuals with diabetes. Diabetes Care 27: 914–920.
18. Lustman, P.J. et al. 2000. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23: 934.
19. Ciechanowski, P.S., W.J. Katon & J.E. Russo. 2000. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch. Intern. Med. 160: 3278.
20. Black, S.A., K.S. Markides & L.A. Ray. 2003. Depression predicts increased incidence of adverse health outcomes in older Mexican Americans with type 2 diabetes. Diabetes Care 26: 2822.
21. De Groot, M., R. Anderson, K.E. Freedland, et al. 2001. Association of depression and diabetes complications: a meta-analysis. Psychosom. Med. 63: 619–630.
22. Ciechanowski, P.S., W.J. Katon, J.E. Russo & I.B. Hirsch. 2003. The relationship of depressive symptoms to symptom reporting, self-care and glucose control in diabetes. Gen. Hosp. Psychiatry 25: 246–252.
23. Lustman, P.J. et al. 1997. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom. Med. 59: 241–250.
24. Lustman, P.J., L.S. Griffith, K.E. Freedland, et al. 1998. Cognitive behavior therapy for depression in type 2 diabetes mellitus. Ann. Intern. Med. 129: 613.
25. Lustman, P.J., K.E. Freedland, L.S. Griffith & R.E. Clouse. 2000. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 23: 618–623.
26. Katon, W.J. et al. 2004. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. Arch. Gen. Psychiatry 61: 1042.
27. Cohen, S., D. Janicki-Deverts & G.E. Miller. 2007. Psychological stress and disease. JAMA 298: 1685–1687.
28. Cosgrove, M.P., L.A. Sargeant, R. Caleyachetty & S.J. Griffin. 2012. Work-related stress and type 2 diabetes: systematic review and meta-analysis. Occup. Med. (Lond.) 62: 167–173.
29. Chida, Y. & M. Hamer. 2008. An association of adverse psychosocial factors with diabetes mellitus: a meta-analytic review of longitudinal cohort studies. Diabetologia 51: 2168–2178.
30. Heraclides, A., T. Chandola, D.R. Witte & E.J. Brunner. 2009. Psychosocial stress at work doubles the risk of type 2 diabetes in middle-aged women: evidence from the Whitehall II study. Diabetes Care 32: 2230–2235.
31. Kato, M. et al. 2009. Psychological factors, coffee and risk of diabetes mellitus among middle-aged Japanese: a population-based prospective study in the JPHC study cohort. Endocr. J. 56: 459–468.
32. Rod, N.H., M. Grønbaek, P. Schnohr, et al. 2009. Perceived stress as a risk factor for changes in health behaviour and cardiac risk profile: a longitudinal study. J. Intern. Med. 266: 467–475.
33. Williams, E.D., D.J. Magliano, R.J. Tapp, et al. 2013. Psychosocial stress predicts abnormal glucose metabolism: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Ann. Behav. Med. 46: 62–72.
34. Novak, M. et al. 2013. Perceived stress and incidence of type 2 diabetes: a 35-year follow-up study of middle-aged Swedish men. Diabet. Med. 30: e8–e16.
35. Virtanen, M. et al. 2014. Psychological distress and incidence of type 2 diabetes in high-risk and low-risk populations: the Whitehall II Cohort Study. Diabetes Care 37: 2091–2097.
36. Mommersteeg, P.M., R. Herr, W.P. Zijlstra, et al. 2012. Higher levels of psychological distress are associated with a higher risk of incident diabetes during 18 year follow-up: results from the British household panel survey. BMC Public Health 12: 1109.
37. Gebreab, S.Y. et al. 2012. The contribution of stress to the social patterning of clinical and subclinical CVD risk factors in African Americans: the Jackson Heart Study. Soc. Sci. Med. 75: 1697–1707.
38. Stetler, C. & G.E. Miller. 2011. Depression and hypothalamic–pituitary–adrenal activation: a quantitative summary of four decades of research. Psychosom. Med. 73: 114–126.
39. Golden, S.H. 2007. A review of the evidence for a neuroendocrine link between stress, depression and diabetes mellitus. Curr. Diabetes Rev. 3: 252–259.
40. Dietrich, A. et al. 2013. Cortisol in the morning and dimensions of anxiety, depression, and aggression in children from a general population and clinic-referred cohort: an integrated analysis. The TRAILS study. Psychoneuroendocrinology 38: 1281–1298.
41. Dienes, K.A., N.A. Hazel & C.L. Hammen. 2013. Cortisol secretion in depressed, and at-risk adults. Psychoneuroendocrinology 38: 927–940.
42. Adam, E.K. et al. 2010. Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence. Psychoneuroendocrinology 35: 921–931.
43. Carnegie, R. et al. 2014. Cortisol awakening response and subsequent depression: prospective longitudinal study. Br. J. Psychiatry 204: 137–143.
44. Sjögren, E., P. Leanderson & M. Kristenson. 2006. Diurnal saliva cortisol levels and relations to psychosocial factors in a population sample of middle-aged Swedish men and women. Int. J. Behav. Med. 13: 193–200.
45. Vreeburg, S.A. et al. 2009. Major depressive disorder and hypothalamic–pituitary–adrenal axis activity: results from a large cohort study. Arch. Gen. Psychiatry 66: 617.
46. Knorr, U., M. Vinberg, L.V. Kessing & J. Wetterslev. 2010. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. Psychoneuroendocrinology 35: 1275–1286.
47. Jarcho, M.R., G.M. Slavich, H. Tylova-Stein, et al. 2013. Dysregulated diurnal cortisol pattern is associated with glucocorticoid resistance in women with major depressive disorder. Biol. Psychol. 93: 150–158.
48. Grynderup, M.B. et al. 2013. A two-year follow-up study of salivary cortisol concentration and the risk of depression. Psychoneuroendocrinology 38: 2042–2050.
49. Vammen, M.A. et al. 2014. Salivary cortisol and depression in public sector employees: cross-sectional and short term follow-up findings. Psychoneuroendocrinology 41: 63–74.
50. Vreeburg, S.A. et al. 2013. Salivary cortisol levels and the 2-year course of depressive and anxiety disorders. Psychoneuroendocrinology 38: 1494–1502.
51. Lok, A. et al. 2012. Longitudinal hypothalamic–pituitary–adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 37: 892–902.
52. Bockting, C.L.H. et al. 2012. Lower cortisol levels predict recurrence in remitted patients with recurrent depression: a 5.5 year prospective study. Psychiatry Res. 200: 281–287.
53. Hardeveld, F. et al. 2014. Increased cortisol awakening response was associated with time to recurrence of major depressive disorder. Psychoneuroendocrinology 50: 62–71.
54. O'Brien, J.T., A. Lloyd, I. McKeith, et al. 2004. A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am. J. Psychiatry 161: 2081–2090.
55. Kohler, S. et al. 2010. White matter hyperintensities, cortisol levels, brain atrophy and continuing cognitive deficits in late-life depression. Br. J. Psychiatry 196: 143–149.
56. Belvederi Murri, M. et al. 2014. HPA axis and aging in depression: systematic review and meta-analysis. Psychoneuroendocrinology 41: 46–62.
57. Rhebergen, D. et al. 2015. Hypothalamic–pituitary–adrenal axis activity in older persons with and without a depressive disorder. Psychoneuroendocrinology 51: 341–350.
58. Dedovic, K. & J. Ngiam. 2015. The cortisol awakening response and major depression: examining the evidence. Neuropsychiatr. Dis. Treat. 11: 1181–1189.
59. Hinkelmann, K. et al. 2012. Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study. Psychoneuroendocrinology 37: 685–692.
60. McKay, M.S. & K.K. Zakzanis. 2010. The impact of treatment on HPA axis activity in unipolar major depression. J. Psychiatr. Res. 44: 183–192.
61. Zobel, A.W. et al. 2000. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34: 171–181.
62. Anacker, C., P.A. Zunszain, L.A. Carvalho & C.M. Pariante. 2011. The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 36: 415–425.
63. Chrousos, G.P. 1995. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332: 1351–1362.
64. Tsigos, C. & G.P. Chrousos. 2002. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53: 865–871.
65. Adam, E.K. & M. Kumari. 2009. Assessing salivary cortisol in large-scale, epidemiological research. Psychoneuroendocrinology 34: 1423–1436.
66. Steffen, P.R., M. McNeilly, N. Anderson & A. Sherwood. 2003. Effects of perceived racism and anger inhibition on ambulatory blood pressure in African Americans. Psychosom. Med. 65: 746–750.
67. Miller, G.E., S. Cohen & A.K. Ritchey. 2002. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. Health Psychol. 21: 531–541.
68. Suglia, S.F. et al. 2010. Cumulative stress and cortisol disruption among black and Hispanic pregnant women in an urban cohort. Psychol. Trauma 2: 326–334.
69. Chida, Y. & A. Steptoe. 2009. Cortisol awakening response and psychosocial factors: a systematic review and meta-analysis. Biol. Psychol. 80: 265–278.
70. Rudolph, K.E. et al. 2016. Job strain and the cortisol diurnal cycle in MESA: accounting for between- and within-day variability. Am. J. Epidemiol. 183: 497–506.
71. Liao, J., E.J. Brunner & M. Kumari. 2013. Is there an association between work stress and diurnal cortisol patterns? Findings from the Whitehall II study. PLoS One 8: e81020.
72. Skinner, M.L., E.A. Shirtcliff, K.P. Haggerty, et al. 2011. Allostasis model facilitates understanding race differences in the diurnal cortisol rhythm. Dev. Psychopathol. 23: 1167–1186.
73. Fuller-Rowell, T.E., S.N. Doan & J.S. Eccles. 2012. Differential effects of perceived discrimination on the diurnal cortisol rhythm of African Americans and Whites. Psychoneuroendocrinology 37: 107–118.
74. Zeiders, K.H., L.T. Hoyt & E.K. Adam. 2014. Associations between self-reported discrimination and diurnal cortisol rhythms among young adults: the moderating role of racial–ethnic minority status. Psychoneuroendocrinology 50: 280–288.
75. Bruehl, H., O.T. Wolf & A. Convit. 2009. A blunted cortisol awakening response and hippocampal atrophy in type 2 diabetes mellitus. Psychoneuroendocrinology 34: 815–821.
76. Lederbogen, F. et al. 2011. Flattened circadian cortisol rhythm in type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 119: 573–575.
77. Hackett, R.A., A. Steptoe & M. Kumari. 2014. Association of diurnal patterns in salivary cortisol with type 2 diabetes in the Whitehall II study. J. Clin. Endocrinol. Metab. 99: 4625–4631.
78. Bild, D.E. 2002. Multi-ethnic study of atherosclerosis: objectives and design. Am. J. Epidemiol. 156: 871–881.
79. Champaneri, S. et al. 2012. Diurnal salivary cortisol and urinary catecholamines are associated with diabetes mellitus: the multi-ethnic study of atherosclerosis. Metabolism 61: 986–995.
80. Joseph, J.J. et al. 2015. Diurnal salivary cortisol, glycemia and insulin resistance: the multi-ethnic study of atherosclerosis. Psychoneuroendocrinology 62: 327–335.
81. Duclos, M., P.M. Pereira, P. Barat, et al. 2005. Increased cortisol bioavailability, abdominal obesity, and the metabolic syndrome in obese women. Obes. Res. 13: 1157–1166.
82. Champaneri, S. et al. 2013. Diurnal salivary cortisol is associated with body mass index and waist circumference: the multiethnic study of atherosclerosis. Obesity 21: E56–E63.
83. Kumari, M., T. Chandola, E. Brunner & M. Kivimaki. 2010. A nonlinear relationship of generalized and central obesity with diurnal cortisol secretion in the Whitehall II study. J. Clin. Endocrinol. Metab. 95: 4415–4423.
84. DeSantis, A.S. et al. 2011. Associations of salivary cortisol levels with metabolic syndrome and its components: the multi-ethnic study of atherosclerosis. J. Clin. Endocrinol. Metab. 96: 3483–3492.
85. Kahn, S.E., R.L. Hull & K.M. Utzschneider. 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444: 840–846.
86. Sáinz, N., J. Barrenetxe, M.J. Moreno-Aliaga & J.A. Martínez. 2015. Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 64: 35–46.
87. Spanakis, E.K. et al. 2016. Lack of significant association between type 2 diabetes mellitus with longitudinal change in diurnal salivary cortisol: the multiethnic study of atherosclerosis. Endocrine 53: 227–239.
88. Hackett, R.A., M. Kivimäki, M. Kumari & A. Steptoe. 2016. Diurnal cortisol patterns, future diabetes, and impaired glucose metabolism in the Whitehall II cohort study. J. Clin. Endocrinol. Metab. 101: 619–625.
89. Anagnostis, P., V.G. Athyros, K. Tziomalos, et al. 2009. The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J. Clin. Endocrinol. Metab. 94: 2692–2701.
90. Pivonello, R. et al. 2016. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 4: 611–629.
91. Steptoe, A. et al. 2014. Disruption of multisystem responses to stress in type 2 diabetes: investigating the dynamics of allostatic load. Proc. Natl. Acad. Sci. U.S.A. 111: 15693–15698.
92. Carvalho, L.A. et al. 2015. Blunted glucocorticoid and mineralocorticoid sensitivity to stress in people with diabetes. Psychoneuroendocrinology 51: 209–218.
93. Stranahan, A.M. et al. 2008. Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons. Nat. Neurosci. 11: 309–317.
94. Chan, O. 2005. Hyperglycemia does not increase basal hypothalamo–pituitary–adrenal activity in diabetes but it does impair the HPA response to insulin-induced hypoglycemia. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289: R235–R246.
95. Campbell, J.E. et al. 2010. Regular exercise prevents the development of hyperglucocorticoidemia via adaptations in the brain and adrenal glands in male Zucker diabetic fatty rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 299: R168–R176.
96. Hudson, J.I. et al. 1984. Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus. Arch. Gen. Psychiatry 41: 1086–1089.
97. Rohleder, N., J.M. Wolf & C. Kirschbaum. 2003. Glucocorticoid sensitivity in humans—interindividual differences and acute stress effects. Stress 6: 207–222.
98. Stimson, R.H. et al. 2011. Increased whole-body and sustained liver cortisol regeneration by 11-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition. Diabetes 60: 720–725.
99. Watts, L.M. et al. 2005. Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54: 1846–1853.
100. Beaudry, J.L. et al. 2014. Effects of selective and non-selective glucocorticoid receptor ii antagonists on rapid-onset diabetes in young rats. PLoS One 9: e91248.